Yong Xu

26PUBLICATIONS
37CO-AUTHORS
Biologically active moleculesComputational physiologyMolecular targetsMedical devicesChemical engineering design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jul 17, 2026
Rapid Identification of a Potent, Selective, and Orally Active p300/CBP Bromodomain Inhibitor Bearing an Imidazo[1,2-a]pyridine Scaffold via a Highly Efficient Four-Step Synthesis.

|May 28, 2026
Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor Activity.

|May 18, 2026
Discovery of CZL-149: A Novel, Highly Potent, and Orally Bioavailable Dual Inhibitor Targeting BET and p300/CBP Bromodomains with Strong Antitumor Efficacy.

|Mar 04, 2026
Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy.

Yumin Huang, Guizhen Cheng, Xin Tang

|Feb 17, 2026
Discovery of ZX079 as a Dual PROTAC Degrader Targeting BRD4/CBP in Acute Myeloid Leukemia.

Qiuping Xiang, Yanan Wang, Mengli Gu

|Sep 02, 2025
Discovery of 2-(Pyrazol-4-yl)-quinazolin-4(3H)-one Derivatives as Subnanomolar BRD4 BD2 Inhibitors with High Selectivity via a Bioisosterism Approach.

Shuxia Chen, Jichen Yang, Qiong Wu

Pageof 5

Frequent Collaborators

5 joint publications

Yan Zhang

4 joint publications

Qiuping Xiang

3 joint publications

Ke Ding

3 joint publications

Jinsong Liu